T he vascular endothelium is the innermost layer of the vessel wall and performs the vital task of providing nutrients to the underlying tissue while dynamically regulating the transvascular flux of proteins and inflammatory cells. 1 Adherens junctions (AJs), formed through homotypic adhesions of the extracellular domain of vascular endothelial (VE)-cadherin across contiguous endothelial cells (EC), maintain vascular barrier function. 2 Lipopolysaccharide or endotoxin, a component of the outer membrane of gram-negative bacteria, induces vascular leak by disrupting AJs. [3] [4] [5] AJs can reanneal after injury, thus restoring barrier function. 6, 7 However, impairment of AJ reannealing results in uncontrolled accumulation of protein-rich fluid and inflammatory cells in the underlying tissue, thereby perturbing tissue-fluid homeostasis, which is a hallmark of chronic vascular inflammatory diseases, such as sepsis and acute respiratory distress syndrome (ARDS). 8, 9 Angiopoietins (Ang1 and 2), which ligate the endothelial Tie2 receptor, have a well-recognized role in regulating the stability of developing vessels. 10, 11 Ang1 phosphorylates the Tie2 receptor and promotes endothelial survival, migration, and barrier formation in the mature endothelium. 10, 11 In contrast, Ang2 blocks Tie2 phosphorylation and induces vascular leak by disrupting AJs through activation of actin-myosininduced stress fiber formation. [12] [13] [14] Interestingly, circulating levels of Ang2 have been shown to be consistently higher in patients who die of ARDS or sepsis than the patients who survive these diseases. 9, [15] [16] [17] [18] Ang2 has, therefore, emerged as a predictor of patient's mortality from ARDS and sepsis. Thus, extensive studies are underway to find approaches which can suppress Ang2 generation for rescuing endothelial barrier function. In this regard, Ang1 infusion seems to be a therapeutic approach to counteract Ang2 disruption of the endothelial barrier. 19 However, Ang1 has also been shown to induce pulmonary hypertension, thereby limiting its use in rescuing vascular barrier function. specific mRNAs for translational repression or degradation, resulting in altered expression of the target genes. 23, 24 In sharp contrast to Ang2, microRNA (miR)-150 levels were shown to be decreased in plasma from septic patients. 25, 26 miR-150 has been shown to regulate EC differentiation and vasculogenesis. 27 Thus, we focused on investigating whether miR-150 plays an obligatory role in reannealing AJs and in resolving vascular barrier function by suppressing Ang2 generation. We show here that miR-150 is induced in ECs during recovery from injury. Loss of miR-150 impaired reannealing of AJs, leading to an irreversible increase in endothelial permeability. We show that miR-150 restores barrier function by suppressing Ang2 generation and downstream signaling through targeting the transcription factor (TF) early growth response 2 (EGR2). Additionally, we show that delivery of a miR-150 mimic into the vasculature of wild-type (WT) mice, pretreated with a lethal dose of lipopolysaccharide, reduces EGR2 and Ang2 and promotes survival during sepsis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

MiR-150 Reanneals AJs and Restores Endothelial Barrier Function
Because reannealing of AJs is required for the restoration of basal endothelial barrier function after vascular injury, 1, 2, 7, 28 we addressed the possibility that miR-150 reanneals AJs. Lipopolysaccharide disrupted AJs, leading to interendothelial gap formation in both WT and miR-150 −/− ECs at 6 hours ( Figure 1A ). However, after 24 hours, AJs in ECs from WT mice had reannealed, sealing the interendothelial gaps ( Figure 1A) . Strikingly, AJs failed to reanneal in ECs from miR-150 −/− mice, leaving numerous interendothelial gaps ( Figure 1A ). We consistently found that lipopolysaccharide induced similar increases in transendothelial albumin flux after 6 hours in both WT and miR-150 −/− ECs ( Figure 1B ). Transendothelial albumin flux recovered to basal levels 24 hours after lipopolysaccharide challenge in the WT ECs but remained persistently high in the miR-150 −/− ECs ( Figure 1B ). Loss of miR-150 had no effect on the expression of AJ components, that is, VE-cadherin and β-catenin (data not shown). These observations demonstrate that miR-150 expression in ECs is required for reannealing AJs and thereby promoting endothelial barrier recovery after injury.
MiR-150 Mimic Strengthens AJs and Prevents Endothelial Barrier Disruption
We assessed the effect of upregulating miR-150 levels on 
MiR-150 Resolves Vascular Injury and Promotes Survival of Mice During Sepsis
As proof of the concept that miR-150 annealing of AJs promotes resolution of vascular injury in vivo, we used a mouse model in which lipopolysaccharide induces lung vascular injury that peaks at 4 hours but resolves in next 24 to 48 hours. 3, 7, 29 We observed that lipopolysaccharide increased the lung wet-to-dry weight ratio and transendothelial albumin extravasation into lung parenchyma of both WT and miR-150 −/− mice at 4 hours ( Figure 3A ). However, in contrast to WT mice, an increase in lung vascular permeability persisted in the miR-150 −/− mice ( Figure 3A ). We next induced sepsis using a high dose of lipopolysaccharide or cecal ligation and puncture in WT and miR-150 null mice to assess whether miR-150 reduces mortality from sepsis. We observed that both lipopolysaccharide and cecal ligation and puncture produced an accelerated and increased overall mortality in miR-150 −/− mice relative to WT mice ( Figure 3B ).
Mature miRNAs are generated through a series of steps with initial being transcription of pri-miR followed by processing of this transcript by enzymes, including Drosha and Dicer, to yield a double-stranded ≈22 nt product comprising the mature miRNA guide strand and the miRNA* passenger strand. 23, 24 Thus, we examined the expression of mature miR-150-5p (referred hereafter as miR-150), miR-150-3p* (passenger strand), and pri-miR-150 in lungs and ECs after lipopolysaccharide challenge. We found that miR-150 expression remained unaltered at the peak of lung injury (ie, at 4 hours) but increased by ≈2-fold at 24 and 48 hours ( Figure 3C ), coinciding with the resolution phase of lung injury ( Figure 2A ). However, the expression of miR-150-3p was not altered (1.0±0.0 at 0 hour; 0.89±0.06 at 4 hours and 0.86±0.11 at 24 hours, respectively). Lipopolysaccharide increased the expression of pri-miR-150 at 4 hours by 1.5-fold, which further increased by 3-fold at 24 hours, indicating lipopolysaccharide induces miR-150 expression transcriptionally ( Figure 3D ).
Endothelial MiR-150 Is Required for Resolution of Lung Vascular Injury
We delivered liposomes containing GFP-tagged pre-miR-150 cDNA under the control of the VE-cadherin promoter into WT and miR-150 −/− mouse vasculature 3, 7 to address if restoration of miR-150 expression in ECs is sufficient to resolve the increase in lung vascular permeability produced by lipopolysaccharide. Mice injected with liposomes containing GFPtagged empty vector under the control of the VE-cadherin promoter were used as controls. Using the endothelial marker, CD31, along with FITC (fluorescein isothiocyanate) gating of CD45 − cells, FACS (fluorescence-activated cell sorting) analysis showed that ≈94% of the ECs were GFP + in lungs of mice receiving GFP or GFP-pre-miR-150 constructs, whereas GFP + cells were barely detectable in WT lung homogenates (negative control), thus confirming EC-specific delivery of constructs ( Figure 4A ). Furthermore, pre-miR-150 cDNA but not vector restored miR-150 expression in the lungs of miR-150 −/− mice to levels similar to those seen in the lungs of WT mice under basal conditions ( Figure 4B ). Importantly, restoration of miR-150 in the ECs of miR-150 −/− mice resolved lung vascular injury ( Figure 4C ).
MiR-150 Reanneals AJs by Suppressing Ang2 Generation and Signaling
Unlike miR-150, Ang2 levels have been shown to be higher in plasma of sepsis or ARDS patients. 9, 12, 15, 17, 18, 30 Thus, we addressed the possibility that miR-150 functioned by suppressing Ang2 generation and downstream signaling. We found that basal levels of Ang2 did not differ between WT and miR-150 null ECs or lungs ( Figure 5A and 5B). As expected, lipopolysaccharide increased the expression of Ang2 in WT ECs and lungs during injury, that is, at 4 hours ( Figure 5A and 5B), but expression returned to basal levels within 24 hours ( Figure 5A and 5B). In contrast, miR-150 −/− ECs or lungs displayed persistent Ang2 generation after lipopolysaccharide treatment even after 24 hours ( Figure 5A and 5B). Transduction of the miR-150 mimic in WT and miR-150 −/− ECs suppressed Ang2 generation, corroborating the above findings that miR-150 terminates Ang2 generation ( Figure 5C ). −/− endothelial cells (ECs) were transfected with miR-150 mimic or control mimic (ctrl) for 48 h. miR-150 expression was quantified taking U6 as the internal control (Inset). Transfected cells were stimulated with LPS (1 μg/mL) for the indicated time points, and adherens junction (AJ) reannealing (A) or transendothelial albumin flux (B) were determined. n=3. All data are mean±SEM. n is the number of experiments. One-way analysis of variance (ANOVA) and post hoc t test were used to compare data between groups. *P<0.05.
Ang2 disrupts AJs through actin-myosin-induced stress fiber formation. 9 Thus, we depleted Ang2 using siRNA ( Figure 
MiR-150 Suppresses Ang2 by Targeting EGR2
Multiple TFs, including NFAT (nuclear factor of activated T cells), FOXO1 (forkhead box protein O1), FOXC2 (forkhead box C2), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), TAL1 (T-cell acute lymphocytic leukemia 1), LYL1 (lymphoblastic leukemia-associated hematopoiesis regulator 1), LMO2 (LIM domain only 2), and HIF2α (hypoxia-inducible factor-2 alpha), are thought to regulate Ang2 expression in various cell types, including ECs. [32] [33] [34] We used miR walk, an online database for predicting miRNA targets, 35 to assess whether miR-150 targets Ang2 or the Ang2-inducing TFs listed earlier. However, neither Ang2 nor any of the above mentioned TFs were found to be major targets of miR-150. Prediction analysis indicated the EGR2 to be the major target of miR150. EGR2 has a single conserved miR-150 binding site in its 3′UTR (untranslated region) sequence with a seed length of 10. Analysis of the Ang2 promoter sequence also revealed the presence of a putative binding site for EGR2 at positions −59 to −51. Thus, we determined EGR2 luciferase reporter activity in human pulmonary arterial ECs co-transducing WT or mutated EGR2 luciferase reporter (Mut-EGR2) and pre-miR-150 cDNAs. miR-150 significantly decreased the WT-EGR2 luciferase activity ( Figure 6A ). However, this response was absent in cells transducing Mut-EGR2 ( Figure 6A ). These findings demonstrate that miR-150 directly targets EGR2. Consistently, EGR2 expression was significantly downregulated in ECs expressing the miR-150 mimic ( Figure We next immunostained human pulmonary arterial ECs (with or without prior lipopolysaccharide treatment) with anti-EGR2 antibody. We first determined the expression of miR-150 in human pulmonary arterial ECs after exposure to lipopolysaccharide. Lipopolysaccharide induced miR-150 expression at 12 hours, which persisted ≤24 hours ( Figure IIB in the online-only Data Supplement). We found that EGR2 was primarily localized in the cytosol in unstimulated human pulmonary arterial ECs. Treatment with lipopolysaccharide increased EGR2 expression at 6 hours, and importantly, −/− impairs resolution of vascular injury and increases sepsis mortality. A, Lung wet-dry ratio (left) and transendothelial albumin influx (EBAE) from lungs or plasma (right) were quantified after exposing indicated mice to nebulized (1 mg/mL) lipopolysaccharide (LPS; n=4-5). B, Mice were challenged with LPS (intraperitoneal 40 mg/kg body weight; left) or cecal ligation and puncture (CLP) was induced (right). n=10. C and D, Wild-type (WT) mice were exposed to nebulized (1 mg/mL) LPS, and lungs were harvested to quantify alteration in miR-150-5p (left) or pri-miR-150 (right) (n=4-5). miR-150 expression is quantified taking U6 as an internal control, whereas GAPDH was used as an internal control for quantifying pri-miR-150 expression. All bar graphs show mean±SEM. n is the number of mice/group. One-way analysis of variance (ANOVA) and post hoc t test were used to compare data between groups (A, C, and D). *P<0.05. In B, mice survival from sepsis was assessed using log-rank test. miR indicates microRNA.
higher levels of EGR2 were found in the nucleus. EGR2 levels returned to near basal levels 24 hours after lipopolysaccharide challenge ( Figure IIC in the online-only Data Supplement). To examine whether EGR2 expression is causally related to Ang2 generation that disrupts barrier function, we depleted EGR2 by ≈70% using siRNA ( Figure 6C, inset) . We observed that lipopolysaccharide failed to induce Ang2 expression ( Figure 6C , left) and MLC phosphorylation, disruption of AJs, and barrier function (Figure 6C , right; and Figure IID in the onlineonly Data Supplement). EMSA (electrophoretic mobility shift assay) assay showed that lipopolysaccharide increased DNAAng2 binding at 6 hours in control cells, which returned to baseline at 24 hours ( Figure 6D ). However, lipopolysaccharide failed to induce these responses in cells depleted of EGR2.
MiR-150 Mimic Reduces Mice Mortality From Sepsis
Systemic and local delivery of miRNA mimics have been shown to have therapeutic effects in mice. 36 We set out to determine whether miR-150 can be therapeutically exploited in the setting of sepsis by targeting Ang2 generation. We delivered a single-dose of miR-150 mimic or a control mimic conjugated within liposomes into the vasculature of WT mice followed by intraperitoneal injection of a lethal dose of lipopolysaccharide ( Figure 6E ). Quantitative polymerase chain reaction analysis of the lung tissue showed that the miR-150 mimic caused a 3.2±0.25-fold increase in miR-150 expression above the control value. Compared with the control mimic, the miR-150 mimic significantly reduced EGR2 and Ang2 expression in lungs and increased survival by 50% at 20 hours and by 25% at 60 hours ( Figure 6E and 6F) . Together, these findings demonstrate that enhancing miR-150 levels during sepsis may be a promising approach for suppressing Ang2 expression and, hence, prevention of sepsis-induced lethality.
Discussion
We have identified a novel role of miR-150 in ECs in reannealing AJs and thereby promoting barrier recovery after injury induced by lipopolysaccharide. We showed that miR-150 suppresses Ang2 generation by targeting the TF, EGR2, and thereby limits EC contraction and AJ disruption after lipopolysaccharide challenge. Loss of miR-150, therefore, led to unrestrained Ang2 generation and downstream signaling, thus impairing resolution of vascular injury. Also, miR-150 null mice had a higher mortality rate after sepsis than WT mice, whereas vascular delivery of a miR-150 mimic opposed these effects. We propose miR-150 as a new therapeutic tool for suppressing Ang2 generation and for promoting resolution of endothelial barrier dysfunction after vascular injury in conditions, such as sepsis and lung injury.
A persistent increase in endothelial permeability is a hallmark of several chronic inflammatory vascular diseases, including sepsis and ARDS. 1, 2, 8 AJs play a key role in maintaining endothelial barrier function.
1,2 Permeability increasing mediators, such as lipopolysaccharide, disassemble AJs but several studies showed that AJs can reform. [3] [4] [5] [6] [7] 37 miRNAs can suppress or augment cellular signaling in several cell types, including ECs based on their ability to target mRNA. 24, 38 Surprisingly, only a few studies have addressed the role of miR in regulating AJ function. For example, Young et al showed that miR-27a targets VE-cadherin and thereby induces vascular leak during ischemia and reperfusion injury. 38 In this study, we sought to identify a miR that can facilitate reformation of AJs after endothelial injury. miR-150 was shown to be a lipopolysaccharide -responsive miR. 39 Moreover, miR-150 expression was shown to be reduced in septic patients. 25, 26 These findings prompted us to investigate the role of miR-150 in reannealing AJs. We showed that the expression of mature miR-150-5p but not miR-150-3p was induced during recovery from endothelial injury post lipopolysaccharide challenge. Mature miRNAs are generated through binding of TF to the promoter region upstream of a precursor (pri-mRNA) sequence, leading to induction of Pri-miR-150. Consistently, we showed that lipopolysaccharide increased Pri-miR-150, albeit earlier than mature miR-150 expression, indicating that after injury, a parallel sequence of events takes place to transcriptionally induce miR-150. However, the identity of the TF that induces miR-150 remains to be unraveled. We also showed that loss of miR-150 did not alter AJ organization or barrier function under basal conditions but markedly impaired Representative FACS (fluorescence-activated cell sorting) plots are shown from experiments which were repeated at least 3 times. (B) miR-150 expression in lungs of WT mice (negative control) or miR-150 null mice receiving GFP vector or pre-miR-150 cDNA. miR-150 expression was quantified taking U6 as the internal control. n=3-4. C, Lung wet-dry ratio were determined at indicated times. n=3-4. n is number of mice. All bar graphs show mean±SEM. One-way analysis of variance (ANOVA) and post hoc t test were used to compare data between groups. *P<0.05.
AJ reannealing after lipopolysaccharide challenge, leading to persistent lung vascular injury. miR-150 null mice also die rapidly after sepsis. We conclude from these findings that miR-150 serves as a key endogenous mechanism to reanneal AJs, restoring thereby endothelial barrier function.
Ang2, a naturally occurring antagonist of Ang1, blocks the Tie2 receptor and induces vascular leak by disrupting AJs. [12] [13] [14] 40, 41 Despite the evidence that unrestrained generation of Ang2 underlies the high mortality associated with ARDS or sepsis, 9,15-18 means to dampen Ang2 levels during vascular injury remain unknown. Interestingly, we showed that although Ang2 levels were reduced during recovery from endothelial injury, miR-150 was found to have been induced. Loss of mir-150 abolished this relationship because the Ang2 level remained elevated in miR-150 null ECs and lungs. Conversely, depletion of Ang2 in miR-150 rescued AJ reannealing and barrier function, demonstrating that miR-150 functioned by suppressing Ang2 generation. Ang2 disrupts AJs by stimulating actin-myosin-induced cell contractility mediated through RhoA-Rho kinase signaling.
1,2,9,42 Consistently, we showed that depletion of Ang2 in miR-150 null ECs suppressed MLC phosphorylation and rescued barrier function. Furthermore, inhibition of MLC phosphorylation using Rho kinase inhibitor Y27632 resolved edema in miR-150 null lungs. Thus, our findings for the first time identify miR-150 as a suppressor of Ang2 generation and signaling.
ECs are known to secrete paracrine factors, including miRs, into the circulation through exosomes. 43, 44 We showed that restoration of miR-150 expression in the endothelium of miR-150 −/− mice via a VE-cadherin promoter-driven vector resolved vascular injury in miR-150 −/− mouse lungs. We also showed that vascular delivery of synthetic miR mimic in the setting of sepsis reduced mouse mortality. Thus, our findings suggest that EC generation of miR-150 may be crucial for maintaining circulating miR-150 and, thereby, Ang2 levels and that impairment of miR-150 generation from ECs may be a contributing factor to the high mortality of patients suffering from sepsis as reported. 25, 26, 45 Because miR can suppress both RNA and protein by targeting 3′UTR sequences in genes, 24 we searched for evidence that miR-150 directly targets Ang2. However, our findings showed that loss of miR-150 does not increase basal Ang2 levels, but rather suppresses Ang2 generation facilitating recovery of barrier function. Thus, we focused on identifying TFs that have been shown to induce Ang2. 32, 34, 46, 47 For example, lipopolysaccharide was shown to enhance Ang2 expression through activation of TFs NF-κB and AP-1 (activator protein-1). 46 Other studies showed the role of NFAT, FOXO, or FOXC2 in inducing Ang2 expression. 32, 34, 47 However, none of these TFs were predicted to be ubiquitous targets of miR-150. The prediction search shortlisted EGR2 as a specific target of miR-150, and interestingly, we found that the Ang2 promoter has a 9 bp GC-rich EGR-binding element (GCGT/ GGGGCG).
48 EGR2 belongs to the EGR family of zinc finger TFs, which can be induced by various extracellular signals, such as growth factors and cytokines, through nonredundant cell-specific intracellular signaling pathways. [48] [49] [50] We showed that miR-150 targets EGR2 and that EGR2 directly binds the Ang2 promoter sequence. Consistently, we showed that in WT lungs, EGR2 expression increased transiently but remained persistently elevated in the lungs of miR-150 −/− mice. Induction of miR-150 or depletion of EGR2 suppressed Ang2 generation and downstream signaling, thereby accelerating resolution of lung injury in miR-150 −/− mice. We showed that basal expression of EGR2 is greater in miR-150 −/− mice than in WT mice. However, miR-150 −/− mice did not show any increase in basal Ang2 levels in ECs or apparent phenotypic changes in the lung. We showed that EGR2 is mainly localized to the cytosol under basal conditions, but treatment with lipopolysaccharide increased EGR2 expression and translocation to the nucleus −/− endothelial cells (ECs; A) or lungs (B) after exposure to lipopolysaccharide (LPS). Ang2 was quantified using Ang2 antibody taking actin as a loading control in panel A (n=3), whereas B shows Ang2 levels in lungs determined using ELISA assay (n=4-5). C, WT or miR-150 −/− ECs were transfected with either control mimic (ct) or miR-150 mimic (mimic). Ang2 expression was determined using anti-Ang2 antibody taking actin as a loading control (n=3). All data represents mean±SEM. In all immunoblots, band density was quantified taking actin as the control. In A and C, n is the number of experiments, whereas in B, n is the number of mice. One-way analysis of variance (ANOVA) and post hoc t test were used to compare data between groups. *P<0.05.
in human ECs. Because this translocation to the nucleus may be coupled to TF activation, 51 our findings suggest that, in addition to EGR2 induction, nuclear transport by extracellular signals may be required for EGR2 activity. Hence, our results demonstrate that miR-150, by targeting EGR2 activity, prevents long-lasting Ang2 generation and thereby resolves vascular injury. In this regard, our findings suggest a new way to control Ang2 generation and downstream signaling through the induction of miR-150 expression.
miRNA mimics are being currently used in several disorders, such as cancer. 36 We have also shown that a single dose of miR-150 mimic delivered in the vasculature of WT mice during sepsis reduced EGR2 and Ang2 expression and their mortality from sepsis, indicating the therapeutic relevance of our findings.
In conclusion, we have demonstrated a key role of miR-150 in reannealing AJs and, thereby, resolving vascular injury by downregulating the generation of Ang2 and barrier disruptive signaling. We showed that miR-150 serves this function by targeting EGR2. Consistently, a single dose of miR-150 mimic liposomes decreased Ang2 levels and mortality from sepsis in WT mice. Although Ang1 infusion can counteract Ang2 effects, it was shown to induce pulmonary hypertension. [20] [21] [22] 52 Thus, our findings identify miR-150 as a new therapeutic strategy for suppressing Ang2 generation and for rescuing endothelial barrier function after vascular injury. . RNA was normalized against GAPDH, whereas immunoblot with anti-actin antibody was used as a loading control. C, Ang2 expression (left) and transendothelial albumin flux (right) in HPAECs depleted of EGR2 after 1 μg/mL LPS challenge. EGR2 depletion was assessed in HPAECs after 48 h transfection with scrambled (siSc) or EGR2 siRNA (SiEGR2; n=3 experiments). D, EMSA (electrophoretic mobility shift assay) of control or EGR2-depleted HPAECs after LPS challenge using 32 P-labeled Ang2 oligonucleotide (n=3 experiments). E, Liposomes conjugated with either miR-150 mimic or control mimic were delivered into vasculature of mice (top). Forty-five min later, these mice were challenged with a lethal dose of LPS (40 mg/kg), and mice survival was monitored over the next 72 h. n=8 in each group. F, EGR2 and Ang2 expression in mice receiving miR-150 mimic versus negative control. n=3-4. All data represent mean±SEM. In all immunoblots, band density was quantified taking actin as the control. Survival was assessed by log-rank test in panel E, whereas in all other panels, 1-way ANOVA and post hoc t test were used to compare data between groups. *P<0.05. EC indicates endothelial cells.
